Clinical Trials Logo

Citation(s)

  •   Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ
    AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020 Feb;182(2):316-326. doi: 10.1111/bjd.18220. Epub 2019 Sep 26.
  •   Khandpur S, Sondhi P, Taneja N, Sharma P, Das D, Sharma A, Sreenivas V
    Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series. J Am Acad Dermatol. 2020 Jul;83(1):248-251. doi: 10.1016/j.jaad.2019.12.071. Epub 2020 Feb 19.
  •   Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ
    Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. Am J Clin Dermatol. 2020 Aug;21(4):483-491. doi: 10.1007/s40257-020-00507-1. Review.

Retrospective Observational Study to Analyze the Effectiveness of Adalimumab

Details for clinical trial NCT04808739